Thank you to all of our delegates, presenters and sponsors for joining us at another successful ASM.  

We had the pleasure of three distinguished international speakers, Dr David Tan (Medical Oncologist, Singapore), Dr Remi Nout  (Radiation Oncologist, Netherland), Dr Anil Sood (Gynaecological Oncologist, MD Anderson, Texas) providing keynote addresses. We also had outstanding speakers from Australia and New Zealand. In addition, Roche Australia will be providing a Breakfast Symposium with Prof Rob Coleman (Gynaecological  Oncologist, MD Anderson, Texas) as keynote speaker via video call and Prof Bradley Monk.

Inspired by the theme “Making a difference for women with gynaecological cancer”, the ASM will also host our third Pure Science Symposium on Wednesday afternoon. Other sessions at the ASM  included:

*  Improving Clinical Practice for Women with Cancer; 
*  Reducing the Cancer Burden; 
*  Improving Quality of Life, and 
*  New Horizons - Bench to Bedside 

ANZGOG continued its popular series of specialty workshops with  Concept Development, Radiation Oncology, and education workshops for Study Coordinators, Consumers and Gynaecological Cancer Nurses.

We would like to thank members of the ANZGOG Scientific Meeting Program Committee for helping to organise the Annual Scientific Meeting 2017. 

We hope all who attended had a stimulating, educational and rewarding meeting.  Look forward to welcoming you to Brisbane in 2018.

Kind Regards

Associate Professor Peter Sykes                        Associate Professor Alison Brand
ASM Committee Chair                                           ANZGOG Chair


Gynonc NZ - Peter Sykes - ANZGOG ASM Chair
Gynonc NSW – Alison Brand - ANZGOG Chair

Medonc ACT – Alison Davis - Research Advisory Committee
Medonc/QoL NSW – Kate Webber
Medonc VIC –Sumitra Ananda
Medonc QLD – Jeff Goh
Medonc SA – Ganessan  Kichenadasse
Gynonc WA – Raj Ganendra
Gynonc VIC - Peter Grant
Gynae WA - Paul Cohen

Radonc VIC – Pearly Khaw
Radonc NSW – Viet Do
MedOnc VIC - Clare Scott - Translational Research

Research Scientist QLD – Pamela Pollock - Translational Research
Study Coordinator – Sue Brew 
ANZGOG Chief Executive Officer:  Alison Evans
Professional Conference Organiser:  YRD (Aust) Pty Ltd – Kate Murphy 


Dr David Tan, Medical Oncologist, Singapore

Dr David Tan is a consultant medical oncologist and clinician scientist at the National University Cancer Institute, Singapore.  His primary clinical and research interests are in gynaecological cancers and the development of novel anti-cancer therapeutic agents. 

Dr Tan graduated with a BSc in Experimental Pathology (1st Class Honours) and MBBS with Distinction from Guy’s, King’s and St Thomas’ School of Medicine, University of London, UK. He undertook training in internal medicine at Hammersmith Hospital and Guy’s and St Thomas’ Hospitals in London, and obtained his MRCP(UK) in 2005. In that same year, he was awarded a Cancer Research UK (CRUK) Clinical Research Fellowship at The Institute of Cancer Research (the academic partner institution of The Royal Marsden Hospital), London, where he did research in ovarian and breast cancers and obtained his PhD in Oncology. He subsequently completed his specialist training in Medical Oncology at The Royal Marsden Hospital, London.  After working in the Drug Development Unit at The Royal Marsden Hospital/ Institute of Cancer Research, he went on to complete another fellowship at the Princess Margaret Cancer Centre, University of Toronto, Canada, in Drug Development and Gynaecologic Oncology before returning back to Singapore. 

In addition to his clinical and academic duties, he is currently also the Associate Chairman Medical Board for Research at the National University Hospital, Singapore and Head of the Innovation Transfer Office at National University Health Systems (NUHS).  He is also a member of the Novel Agents Committee for Cancer (NACC) at the Experimental Therapeutics Centre in A*STAR Singapore.  He has authored over 50 peer-reviewed scientific papers and abstracts and received several awards for his research as well.

Sponsored by: 

Dr Remi Nout, Radiation Oncologist, Netherlands

Remi Nout was board certified as Radiation Oncologist in the Netherlands in 2008. During his residency he was involved in the PORTEC (Post Operative Radiation Therapy for Endometrial Cancer) trials. With the thesis titled ‘PORTEC- Reducing Overtreatment and Improving Quality of Life’ he obtained a PhD degree in 2013.The outcomes of the PORTEC-2 trial and long-term quality of life among PORTEC-1 survivors formed the basis of this thesis. He combines clinical work at the Leiden University Medical Center in the Netherlands with research activities and involvement in the PORTEC trials and is co-principal investigator in PORTEC-4. Main research areas include health related quality of life (endometrial cancer, cervical cancer collaborating in the EMBRACE study, rectal cancer), translational research prognostic and predictive markers in endometrial cancer, and brachytherapy. He is active in the GEC-ESTRO GYN group, currently involved a task group for the target concept in endometrial cancer, vaginal recurrences and primary vaginal cancer. He is board member of the Dutch Platform for Radiotherapy of Gynaecological Malignancies and representative in the Dutch Gynecologic Oncology Group. Since March 2014 he was awarded a two-year Clinical Fellowship from the Dutch Cancer Society titled ‘Image Guided Brachytherapy’ with a focus on rectal and gynaecological cancers. During this fellowship he will work in the radiotherapy departments of the Jewish General Hospital in Montreal, Canada; Aarhus University Hospital, Denmark; University Medical Center Utrecht, Erasmus Medical Center Rotterdam and the Leiden University Medical Center in the Netherlands.

Sponsored by: 

Dr Anil Sood, Gynaecologic Oncologist, USA

Dr. Anil K. Sood is Professor and Vice Chair for Translational Research in the Departments of Gynecologic Oncology and Cancer Biology and co-director of the Center for RNA Interference and Non-Coding RNA at the M. D. Anderson Cancer Center. He is also Director of the multi-disciplinary Blanton-Davis Ovarian Cancer Research Program. Dr. Sood co-leads the Women’s Cancer Moonshot Program (focused on ovarian and breast cancers).

Dr. Sood received his medical degree from the University of North Carolina, Chapel Hill, North Carolina. His research is focused in three main areas: 1) mechanisms of angiogenesis and metastasis in ovarian cancer; 2) effects of neuroendocrine stress hormones on ovarian cancer growth and progression, 3) development of new strategies for systemic in vivo siRNA delivery. Dr. Sood has received major recognition for his research accomplishments including the Hunter Award, the Margaret Greenfield/Carmel Cohen Excellence in Ovarian Cancer Research Prize, and the GCF/Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher. Dr. Sood has published over 460 peer-reviewed articles and holds 15 patents related to novel drugs and technologies. He is an elected member of the American Society for Clinical Investigation (ASCI) and an elected fellow of the American Association for the Advancement of Science (AAAS).

Sponsored by: 


Select a registration type



Full registration includes tickets to all social functions.  Early Bird Registration has now closed.
Please read our cancellation policy prior to registering.

Member Medical $1180
Member Non Medical/Trainee $750
Non-Member Medical $1380
Non Member Non Medical/Trainee $950


Wednesday 29th March
1.30PM - 5.00PM

Please note this registration is if you are only able to attend the Pure Science Symposium only.  If you are registering for the full conference attendance included.

Member Medical $195
Member Non Medical/Trainee $195
Non-Member Medical $295
Non Member Non Medical/Trainee $295


Thursday, Friday and Saturday

Member Medical $495
Member Non Medical/Trainee $495
Non-Member Medical $595
Non Member Non Medical/Trainee $595


WELCOME RECEPTION - Peter MacCallum Cancer Centre

Join us on Wednesday 29th March for a not to be missed opportunity to visit the new state of the art facility.  Peter Mac is one of the world’s leading cancer research, education and treatment centres globally and is Australia’s only public hospital solely dedicated to caring for people affected by cancer. With over 2,500 staff, including more than 580 laboratory and clinical researchers, all focused on providing better treatments, better care and potential cures for cancer.

The evening will include tour of the facility with BBQ and drinks in the Loft.  Formalities will commence at 6.30pm.


Join us on Friday 31 March for the Conference Dinner, being held in the Residence at the Grand Hyatt.  The Residence is a private, mansion style event space perfect for the conference dinner. Enjoy a three course meal with your colleagues and friends in a relaxed environment.  By popular demand there will be a live 2 piece band for those that want to dance the night away on the Terrace.

Ticket price is included with your full registration.  Additional tickets may be purchased.

PURE SCIENCE SYMPOSIUM - Wednesday 29th March

In 2017 the Pure Science Symposium will be held on Wednesday 29th March, prior to the Welcome Reception.  More detailed information on the Pure Science Symposium is available in the draft Program.

WORKSHOPS - Friday 31st March



Over the course of the last few years, the treatment of gynaecologic cancer has evolved quite rapidly.  New scientific and therapeutic advances in surgery, systemic agents and radiotherapy have modified the standard of care; all aimed at improving patient outcomes and quality of life.

During the same period, the treatment of gynaecologic cancer has increased in complexity.  It now requires the input of a multidisciplinary team.  In radiation oncology, the open communication and harmony between different craft groups (medical physics, radiation therapy, and radiation oncology) has facilitated this team approach in providing the best care for patients.

This workshop will bring together all you need to know on the radiotherapy-related management of the complex vulvar cancer patient and in localised recurrence of gynaecological cancer.  It is hopeful that this will provide the up-to-date information for you to select the best treatment strategies for your patients.



Bring a one sentence or single paragraph ideas for development.  We have places for a maximum of 16 researchers with a concept idea to develop further at the workshop.  Please confirm your workshop registration ASAP as spaces filling fast.  Send in your idea to Anna Kraszewski at  by Friday 26 February 2017.  

You will get to discuss your concept in small groups with two clinical advisers and a statistian as well as with other clinical specialists who will be in attendance to assist. 





The incidence and mortality of endometrial cancer continue to grow, which is in no small part a result of the worldwide obesity epidemic. This workshop will address some of the issues in endometrial cancer including current management, current and future trials, obesity and diet, exercise, new approaches to follow up of low grade endometrial cancer and psychological issues.



FREE GCP REFRESHER COURSE - Wednesday 29th March 1.30PM - 5.00PM


All Conference Attendees Welcome to attend - Eleanor Allan returns by popular demand.

In November 2016 ICH GCP E6 Revision 2 was issued – the first change to GCP since its debut in 1996.  Come and join in the conversation on the key major changes for sites and sponsors, what it might mean for your day-to-day work, and how to approach some of the potential challenges the changes may bring about.

ANZGOG EVENING SYMPOSIUM - Thursday 30th March at 5.45pm

Topic | Practical guidance on the use of olaparib in women with PSR BRCAm HGSOC

Panel |  Prof Michael Friedlander (chair) A/Prof Linda Mileshkin, A/Prof Catherine Shannon

ANZGOG delegates are invited to attend a Satellite Symposium provided by Astra Zeneca.  Please join us at 5:45pm, following the poster viewing session.

Overview: Prof Michael Friedlander (chair) A/Prof Catherine Shannon , A/Prof Linda Mileshkin will lead a practical case based discussion on the use of olaparib in women with PSR BRCAm HGSOC.  Delegates will receive practical guidance on patient selection, optimal timing to start maintenance therapy, advice on patient counselling, tips on the management of common side effects and appropriate dosing to ensure patients treated in routine practice receive optimal benefit.

Please register to attend the symposium when registering for the ASM



IMPROVING OUTCOMES IN HGSOC: From targeted trials to targeted therapies

Chair: Dr George AU-Yeung 

International Speakers:
Professor Bradley Monk, Director, Division of Gynaecologic Oncology, University of Arizona Cancer Centre, Phoenix Arizona
Professor Robert Coleman, Department of Oncology and Reproductive Medicines, University of Texas MD Anderson Cancer Centre, Houston, Texas

This meeting brings together international and local experts to discuss how to improve outcomes in ovarian cancer through new approaches to trial design, identifying molecular sub-types and novel targets and the latest evidence for targeted therapies.

Please register to attend the Breakfast when registering for the ASM.

Prof Robert Coleman, Gynaecology Oncology, Texas, USA

Robert L. Coleman, MD is the Ann Rife Cox Professor in Gynecology & Deputy Chair in the Department of Gynecologic Oncology & Reproductive Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas, where he also serves as Vice-Chair, Clinical Research. Dr. Coleman’s research interests include novel therapeutics for gynecologic cancers, clinical trial development and statistical design, surgical innovations, and graduate education. He serves on the NRG’s (formerly the Gynecologic Oncology Group) Ovarian and Developmental Therapeutics Committees, and is PI or co-PI for several prospective clinical trials. He currently is a co-project leader for the MDACC Ovarian SPORE, the MDACC Uterine SPORE, the Ovarian Cancer Research Fund, and CPRIT, each of which is sponsoring novel therapeutics trials in gynecologic cancers. Dr Coleman has authored or coauthored over 500 scientific publications, including over 240 peer-reviewed original research articles, numerous book chapters, monographs, invited articles and textbooks including, The Handbook of Gynecologic Oncology, Clinical Lymphatic Mapping in Gynecologic Cancers, Prognostic and Predictive Factors in Gynecological Cancers, and Atlas of Gynecologic Oncology. Dr Coleman is currently the immediate Past President of the Society of Gynecologic Oncology (2015-2016), Secretary Treasurer for the International Gynecologic Cancer Society, and is an immediate past American Board of Obstetrics and Gynecology, Division of Gynecologic Oncology member.

Prof Bradley Monk, Gynaecology Oncology, Phoenix, USA

Dr. Bradley Monk graduated at the top of his class from the University of Arizona College of Medicine-Tucson in 1988, and completed a residency in Obstetrics and Gynecology at the University of California, Los Angeles, in 1992. Between 1988 and 1995, he was the recipient of three fellowships in Medical Genetics and Gynecologic Oncology. In 1995, Dr. Monk was appointed Director of Gynecologic Oncology at Texas Tech University Health Services Center and, from 1998 until 2010, was Associate Professor with Tenure of the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology at the Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center and Director of Research in the Department of Obstetrics and Gynecology. Dr. Monk was then appointed Director and Professor in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ.  Dr. Monk is also a Professor on the Clinical Scholar Track at the University of Arizona College of Medicine – Phoenix and works at Arizona Oncology (US Oncology Network). He has been named one of Arizona’s “Top Doctors” by PHOENIX magazine 5 years in a row beginning in 2012.

Dr. Monk’s research interests include chemotherapy to treat ovarian and cervical carcinoma; the etiology, biomarkers in gynecologic cancers; and quality of life in women with advanced ovarian cancer. He was the first to report the activity of anti-vascular growth factor (VEGF) therapy in ovarian cancer and his papers in the New England Journal of Medicine led to the global approval of anti-VEGF therapy in recurrent ovarian and cervical cancers in 2014. He was also the lead author on the pivotal trial of trabectedin in recurrent ovarian cancer as well as many other studies that have met their primary endpoints. Dr. Monk was also awarded the highly prestigious Ernst Wertheim Award for his research in cervical cancer and is on the Board of Directors for the GOG Foundation, Inc. and is the Cervical Cancer Sub-Committee Chair for NRG Oncology. He also chairs the Cervical Cancer Committee for the Gynecologic Cancer Intergroup (GCIG). Currently, he is President of the Western Association of Gynecologic Oncologists (WAGO).

Grand Hyatt Melbourne

Located in the heart of Melbourne, the Grand Hyatt Melbourne will host Australia New Zealand Gynaecological Oncology Group Annual Scientific Meeting 2017.  Walking distance from luxurious accommodation, 5-star restaurants and many of Melbourne's main attractions we trust that your experience at the Grand Hyatt Melbourne will be great.

Grand Hyatt

Grand King - Room Only


This modern 33-sq-metre guestroom features a luxurious king size bed facing floor-to-ceiling postcard views of Melbourne's skyline.  The contempory residential room design offers a modern living area and creates a picture-perfect setting to relax.  Enjoy the stunning Italian marble bathroom with separate deep soaking bath tub and shower.


Rydges Melbourne

Deluxe Queen - Room Only


Our Deluxe Queen Rooms are designed with a distinct cosmopolitan style, complete with contemporary furniture and offering great city views. These rooms comprise of a Queen sized bed, flat screen television, reading area, workstation featuring media hub with high-speed internet connection.

Adina Apartments

Adina Apartment Hotel Melbourne Flinders Street is the perfect Melbourne CBD base for experiencing the best of the city’s restaurants, cafés, nightlife, shopping, sports and cultural events.  Located near Flinders Street Station and just one block from Federation Square, you can walk from the hotel to the city’s big venues, iconic landmarks and world-class dining experiences.

1 Bedroom Apartment - SOLD (Apartments may be available on request however conference rate can not be guaranteed, we will aim to get the best price available)


1 Queen or 2 singles (2 guests)

2 Bedroom Apartment -- SOLD


1 King/2 Singles options in either room.

(4 guests max)


Thank you to all of our sponsors. If you are interested in sponsoring ANZGOG ASM 2017 please contact us on the link below for a copy of the sponsorship prospectus.


Sponsorship Prospectus